Wells Fargo
ABEO icon

Wells Fargo’s Abeona Therapeutics ABEO Stock Holding History

Wells Fargo’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$74.8K Sell
16,702
-31,150
-65% -$156K ﹤0.01% 5263
2025
Q4 		$252K Buy
47,852
+20,673
+76% +$104K ﹤0.01% 4934
2025
Q3 		$144K Buy
27,179
+4,319
+19% +$27.4K ﹤0.01% 5122
2025
Q2 		$130K Buy
+22,860
New +$130K ﹤0.01% 5038
2024
Q4 		– Sell
-60
Closed -$379 – 7044
2024
Q3 		$379 Hold
60
– – ﹤0.01% 6185
2024
Q2 		$254 Sell
60
-184
-75% -$939 ﹤0.01% 6191
2024
Q1 		$1.77K Buy
244
+7
+3% +$44 ﹤0.01% 6055
2023
Q4 		$1.19K Buy
237
+69
+41% +$304 ﹤0.01% 6190
2023
Q3 		$707 Buy
168
+40
+31% +$151 ﹤0.01% 6285
2023
Q2 		$516 Buy
128
+15
+13% +$52 ﹤0.01% 6482
2023
Q1 		$319 Buy
113
+64
+131% +$167 ﹤0.01% 6646
2022
Q4 		$151 Buy
49
+14
+40% +$52 ﹤0.01% 6701
2022
Q3 		$0 Sell
35
-4
-10% -$16 ﹤0.01% 6579
2022
Q2 		$0 Buy
39
+3
+8% +$15 ﹤0.01% 6731
2022
Q1 		$0 Buy
36
+11
+44% +$76 ﹤0.01% 6968
2021
Q4 		$0 Hold
25
– – ﹤0.01% 7162
2021
Q3 		$1K Buy
25
+7
+39% +$224 ﹤0.01% 6638
2021
Q2 		$1K Sell
18
-873
-98% -$35.6K ﹤0.01% 6605
2021
Q1 		$42K Sell
891
-2,347
-72% -$129K ﹤0.01% 5887
2020
Q4 		$127K Buy
3,238
+687
+27% +$23.4K ﹤0.01% 5268
2020
Q3 		$65K Sell
2,551
-513
-17% -$32.3K ﹤0.01% 5415
2020
Q2 		$223K Buy
3,064
+1,174
+62% +$81.2K ﹤0.01% 4841
2020
Q1 		$99K Buy
1,890
+1,209
+178% +$80.8K ﹤0.01% 5060
2019
Q4 		$56K Buy
681
+5
+0.7% +$353 ﹤0.01% 5478
2019
Q3 		$38K Buy
676
+57
+9% +$4.27K ﹤0.01% 5634
2019
Q2 		$74K Sell
619
-125
-17% -$21K ﹤0.01% 5419
2019
Q1 		$137K Sell
744
-2
-0.3% -$358 ﹤0.01% 5007
2018
Q4 		$133K Sell
746
-1,245
-63% -$272K ﹤0.01% 5146
2018
Q3 		$637K Buy
1,991
+60
+3% +$21.3K ﹤0.01% 4279
2018
Q2 		$773K Buy
1,931
+67
+4% +$29.3K ﹤0.01% 4171
2018
Q1 		$669K Buy
1,864
+3
+0.2% +$1.11K ﹤0.01% 4196
2017
Q4 		$738K Buy
1,861
+452
+32% +$187K ﹤0.01% 4120
2017
Q3 		$600K Buy
1,409
+1,369
+3,423% +$368K ﹤0.01% 4211
2017
Q2 		$6K Sell
40
-20
-33% -$2.73K ﹤0.01% 5866
2017
Q1 		$8K Buy
+60
New +$7.74K ﹤0.01% 5921
2016
Q4 		– Sell
-8
Closed -$1K – 6230
2016
Q3 		$1K Hold
8
– – ﹤0.01% 6090
2016
Q2 		$0 Sell
8
-40
-83% -$2.73K ﹤0.01% 6070
2016
Q1 		$3K Buy
48
+35
+269% +$2.32K ﹤0.01% 5953
2015
Q4 		$1K Buy
13
+3
+30% +$301 ﹤0.01% 6070
2015
Q3 		$1K Buy
10
+2
+25% +$265 ﹤0.01% 6042
2015
Q2 		$1K Hold
8
– – ﹤0.01% 6209
2015
Q1 		$1K Hold
8
– – ﹤0.01% 6029
2014
Q4 		$1K Buy
+8
New +$717 ﹤0.01% 6068

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Wells Fargo's ABEO Position: Q1 2026 in Review

Wells Fargo reduced its Abeona Therapeutics (ABEO) stake by 65% in Q1 2026, selling an estimated $156K and leaving 16,702 shares worth $74.8K. The position accounts for ﹤0.01% of the portfolio, ranked #5263.

Wells Fargo first reported a position in ABEO in Q4 2014 and has held it in 43 quarters since. The position peaked at $773K in Q2 2018. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

  • Wells Fargo held 16,702 shares of Abeona Therapeutics worth $74.8K as of Q1 2026.
  • Wells Fargo sold 31,150 Abeona Therapeutics shares in Q1 2026, an estimated $156K.
  • Abeona Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #5263 holding.
  • Wells Fargo first reported a position in Abeona Therapeutics in Q4 2014 and has held it in 43 quarters since.
  • Wells Fargo's Abeona Therapeutics position peaked at $773K in Q2 2018.
  • 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.